Results 1 to 10 of about 5,561 (172)
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome [PDF]
Anais Brasileiros de Dermatologia, 2017 Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in ...
Asli Akin Belli +11 more
core +3 more sources
Deferasirox: appraisal of safety and efficacy in long-term therapy
Journal of Blood Medicine, 2013 Preeti Chaudhary, Vinod PullarkatJane Ann Nohl Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles, CA, USAAbstract: Deferasirox is a once-daily, oral iron chelator that is widely used in the management of ...
Chaudhary P, Pullarkat V
core +1 more source
Deferasirox, an oral chelator in the treatment of iron overload
Italian Journal of Medicine, 2013 BACKGROUND Deferasirox is a once-daily oral iron chelator developed for treating iron overload complicating long-term transfusion therapy in patients with diseases such as beta-thalassemia and myelodysplastic syndromes. Iron overload can damage the liver,
I. Portioli
core +3 more sources
Therapeutics and Clinical Risk Management, 2016 Anna W Chalmers, Jamile M Shammo Department of Internal Medicine, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA Abstract: Transfusion-dependent anemia is a common feature in a wide array of hematological disorders ...
Chalmers AW, Shammo JM
core +1 more source
Therapeutics and Clinical Risk Management, 2018 Carmen Fucile,1 Francesca Mattioli,1 Valeria Marini,1 Massimo Gregori,2 Aurelio Sonzogni,3 Antonietta Martelli,1 Natalia Maximova4 1Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy; 2Department of Pediatric Radiology, Institute for ...
Martelli A +7 more
core +2 more sources
Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia [PDF]
PharmacyIron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications.
Saeed Barzegari +3 more
doaj +2 more sources
Update on the use of deferasirox in the management of iron overload
Therapeutics and Clinical Risk Management, 2009 Ali Taher,1 Maria Domenica Cappellini21American University of Beirut, Beirut, Lebanon; 2Universitá di Milano, Policlinico Foundation IRCCS, Milan, ItalyAbstract: Regular blood transfusions as supportive care for patients with chronic anemia ...
Ali Taher +3 more
core +1 more source
Deferasirox improved iron homeostasis and hematopoiesis in ovariectomized rats with iron accumulation [PDF]
Scientific ReportsMenopause is a natural biological aging process characterized by the loss of ovarian follicular function and decrease estrogen levels. These hormonal fluctuations are associated with increased iron levels, which ultimately lead to iron accumulation. This
Niloofar Honari +4 more
doaj +2 more sources
The Possible Protective Role of Vitamin E Against Deferasirox-Induced Injury of Renal Cortical Tubules in Adult Male Albino Rat: A Histological and Immunohistochemical Study [PDF]
The Egyptian Journal of Histology, 2023 Introduction: Deferasirox, as an oral iron chelator, is presently the first-choice medication for iron overload caused by repeated blood transfusions due to its ease of use, efficacy, and high bioavailability, yet deferasirox has been also reported with ...
Shimaa Badr +2 more
doaj +1 more source
Molecules, 2021 Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload. The essential transition metals iron and copper are the primary catalysts of reactive oxygen species
Viktor A. Timoshnikov +4 more
doaj +1 more source